{"product_id":"retatrutide-glp-3","title":"Retatrutide (GLP-3)","description":"\u003cdiv class=\"prod-section\"\u003e\n\u003cdiv class=\"prod-section-label\"\u003e\n\u003ci class=\"ti ti-file-description\"\u003e\u003c\/i\u003eResearch Background\u003c\/div\u003e\n\u003cp class=\"prod-para\"\u003eRetatrutide (LY3437943; CAS 2381247-38-9; MW ~4676 g\/mol) is a 39-amino acid synthetic peptide representing the most advanced generation of incretin-based metabolic research compounds currently in active clinical investigation. Unlike its predecessor compounds — semaglutide (GLP-1 agonist) and tirzepatide (dual GLP-1\/GIP agonist) — retatrutide simultaneously activates three distinct metabolic hormone receptors, offering researchers an unprecedented multi-pathway metabolic probe in a single molecule.\u003c\/p\u003e\n\u003cp class=\"prod-para\"\u003eThe compound is derived from a glucose-dependent insulinotropic polypeptide (GIP) backbone and incorporates three non-coded amino acid substitutions (Aib at positions 2 and 20; alpha-methyl-leucine at position 13) that confer metabolic stability and receptor selectivity. A C20 fatty diacid conjugated at lysine position 17 provides strong albumin binding that dramatically extends plasma half-life, enabling once-weekly dosing intervals in clinical protocols.\u003c\/p\u003e\n\u003cp class=\"prod-para\"\u003eAt the receptor level, retatrutide's three-point engagement produces coordinated metabolic effects greater than the sum of its parts: GLP-1 receptor activation drives glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and hypothalamic appetite signaling; GIPR activation enhances insulin dynamics and adipocyte lipid metabolism; glucagon receptor (GCGR) activation promotes hepatic fat oxidation, energy expenditure, and thermogenesis — differentiating retatrutide from dual agonists. This GCGR component is a key driver of superior fat mass reduction and hepatic steatosis improvement seen in clinical data.\u003c\/p\u003e\n\u003cp class=\"prod-para\"\u003eIn Phase II clinical trials (NEJM, Jastreboff et al., 2023), participants receiving 12 mg weekly achieved mean body weight reduction of 24.2% at 48 weeks. Phase III TRIUMPH trials are ongoing, investigating outcomes in obesity, type 2 diabetes, osteoarthritis, and MASLD.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"prod-section\"\u003e\n\u003cdiv class=\"prod-section-label\"\u003e\n\u003ci class=\"ti ti-atom\"\u003e\u003c\/i\u003ePhysicochemical Data\u003c\/div\u003e\n\u003cdiv class=\"table-scroll\"\u003e\n\u003ctable class=\"prod-table\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCompound\u003c\/th\u003e\n\u003cth\u003eMW \/ Formula\u003c\/th\u003e\n\u003cth\u003eCAS No.\u003c\/th\u003e\n\u003cth\u003eSequence \/ Structure\u003c\/th\u003e\n\u003cth\u003eReceptor \/ Target\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr class=\"row-alt\"\u003e\n\u003ctd class=\"td-bold\"\u003eRetatrutide (LY3437943)\u003c\/td\u003e\n\u003ctd\u003e~4676 g\/mol (acylated)\u003c\/td\u003e\n\u003ctd\u003e2381247-38-9\u003c\/td\u003e\n\u003ctd\u003e39-AA GIP-backbone; Aib2\/Aib20\/aMeL13; C20 fatty diacid at Lys17\u003c\/td\u003e\n\u003ctd\u003eTriple GLP-1R \/ GIPR \/ GCGR agonist; albumin-binding extended half-life\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e","brand":"General Peptide","offers":[{"title":"1 Vial","offer_id":50856747630839,"sku":null,"price":68.0,"currency_code":"USD","in_stock":true},{"title":"3 Vials","offer_id":50856747663607,"sku":null,"price":184.0,"currency_code":"USD","in_stock":true},{"title":"5 Vials","offer_id":50856747696375,"sku":null,"price":272.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0934\/1485\/0807\/files\/Metabolic_Retatrutide-_GLP-3.jpg?v=1781171755","url":"https:\/\/generalpeptide.com\/products\/retatrutide-glp-3","provider":"General Peptide","version":"1.0","type":"link"}